As MedWhat scores an initial win in its courtroom battle with Stanford, Paige.ai finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.
The GUV September issue editorial by Thierry Heles.
Editor-in-chief James Mawson takes an in-depth look at what the Horizon Europe budget needs to achieve.
Editor-in-chief James Mawson takes a look at assumed problems around university IP and considers the opportunities of university venture funds ahead of a report by Hermann Hauser.
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.